FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer

Summary

This phase II trial is studying how well FR901228 works in treating patients with refractory stomach cancer or gastroesophageal junction. Drugs used in chemotherapy, such as FR901228, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. FR901228 may also stop the growth of tumor cells by blocking some of the enzymes needed for their growth.

Timeline

Start

2004-10

Primary completion

2005-09

Completion

—

Drugs

Indications